首页> 外文期刊>Nanotechnology >Hyperthermia-triggered release of hypoxic cell radiosensitizers from temperature-sensitive liposomes improves radiotherapy efficacy in vitro
【24h】

Hyperthermia-triggered release of hypoxic cell radiosensitizers from temperature-sensitive liposomes improves radiotherapy efficacy in vitro

机译:来自温度敏感脂质体的高温触发缺氧细胞辐射敏胶剂的释放改善了体外放射治疗疗效

获取原文
获取原文并翻译 | 示例
获取外文期刊封面目录资料

摘要

Hypoxia is a characteristic feature of solid tumors and an important cause of resistance to radiotherapy. Hypoxic cell radiosensitizers have been shown to increase radiotherapy efficacy, but dose-limiting side effects prevent their widespread use in the clinic. We propose the encapsulation of hypoxic cell radiosensitizers in temperature-sensitive liposomes (TSL) to target the radiosensitizers specifically to tumors and to avoid unwanted accumulation in healthy tissues. The main objective of the present study is to develop and characterize TSL loaded with the radiosensitizer pimonidazole (PMZ) and to evaluate the in vitro efficacy of free PMZ and PMZ encapsulated in TSL in combination with hyperthermia and radiotherapy. PMZ was actively loaded into TSL at different drug/lipid ratios, and the physicochemical characteristics and the stability of the resulting TSL-PMZ were evaluated. PMZ release was determined at 37 degrees C and 42 degrees C in HEPES buffer saline and fetal bovine serum. The concentration-dependent radiosensitizing effect of PMZ was investigated by exposing FaDu cells to different PMZ concentrations under hypoxic conditions followed by exposure to ionizing irradiation. The efficacy of TSL-PMZ in combination with hyperthermia and radiotherapy was determined in vitro, assessing cell survival and DNA damage by means of the clonogenic assay and histone H2AX phosphorylation, respectively. All TSL-PMZ formulations showed high encapsulation efficiencies and were stable for 30 d upon storage at 4 degrees C and 20 degrees C. Fast PMZ release was observed at 42 degrees C, regardless of the drug/lipid ratio. Increasing the PMZ concentration significantly enhanced the effect of ionizing irradiation. Preheated TSL-PMZ in combination with radiotherapy caused a 14.3-fold increase in cell death as compared to radiotherapy treatment alone. In conclusion, our results indicate that TSL-PMZ in combination with hyperthermia can assist in improving the efficacy of radiother
机译:缺氧是实体瘤的特征,以及对放射疗法抗性的重要原因。已显示缺氧细胞辐射胶原胶质剂来增加放疗疗效,但剂量限制副作用可防止其在临床中的广泛使用。我们提出了在温度敏感的脂质体(TSL)中的缺氧细胞辐射胶质化剂的封装,以靶向肿瘤的辐射敏胶剂,并避免在健康组织中的不需要的积累。本研究的主要目的是开发和表征装有辐射敏化剂吡吡唑(PMZ)的TSL,并评估了与热疗和放射治疗组合的自由PMZ和PMZ的体外功效。 PMZ以不同的药物/脂质比地主动装载到TSL中,评价物理化学特性和所得TSL-PMZ的稳定性。在Hepes缓冲盐和胎牛血清中,在37℃和42℃下测定PMZ释放。通过在缺氧条件下将FADU细胞暴露于不同的PMZ浓度,然后暴露于电离照射来研究PMZ的浓度依赖性放射敏化效应。在体外测定TSL-PMZ与热疗和放射疗法组合的疗效,通过克隆核酸分析和组蛋白H2AX磷酸化评估细胞存活和DNA损伤。所有TSL-PMZ配方均显示出高封装效率,并且在4摄氏度下储存时稳定30d,并且在42℃下观察到快速PMZ释放,无论药物/脂质比如何。提高PMZ浓度显着提高了电离辐照的效果。与单独的放射治疗相比,预热TSL-PMZ与放射疗法组合引起的细胞死亡增加14.3倍。总之,我们的结果表明,与热疗组合的TSL-PMZ可以帮助改善放射线的疗效

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号